Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-07-26FDA Approved: BORTEZOMIB — Original Application (Hospira, Inc.)
FDA approved Hospira's generic version of bortezomib for injection under ANDA208460, enabling a generic option for the same indications as t…
-
FDA approval · 2022-07-26FDA Approved: BORTEZOMIB — Original Application (Dr.Reddy's Laboratories, Inc.)
FDA approval of Dr. Reddy's Laboratories' original ANDA for Bortezomib, enabling a generic version of the proteasome inhibitor.
-
FDA approval · 2022-07-26FDA Approved: BORTEZOMIB — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original generic application for bortezomib, a proteasome inhibitor used to treat multiple myeloma and …
-
EMA approval · 2022-07-22New medicine for multiple myeloma patients with limited treatment options
EMA announces a new medicine for multiple myeloma patients with limited treatment options, indicating a potential new treatment option in th…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase II trial evaluating bevacizumab with bortezomib in relapsed/refractory multiple myeloma; study terminated with results posted in 2022.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-07-05Clinical Trial Update: Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]
A Phase 2 trial evaluated alternating ixazomib citrate and lenalidomide as maintenance therapy after stem cell transplantation in patients w…
-
FDA approval · 2022-06-30FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, Inc. The action updates the approved l…
-
FDA label_change · 2022-06-30FDA Approved: LENALIDOMIDE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for lenalidomide submitted by Dr. Reddy's Laboratories Inc., resulting in updated labeling for the d…
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury [Phase 4]
Phase 4 clinical trial evaluating HFR-SUPRA for treatment of multiple myeloma-related acute kidney injury (not yet recruiting).
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion [Phase 2]
Phase 2 clinical trial comparing single agent melphalan to BEAM as a preparative regimen for high-dose therapy with autologous stem cell rei…
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment [Phase 2]
Phase 2 trial evaluating daratumumab with bortezomib and dexamethasone in relapsed/refractory multiple myeloma with severe renal impairment …
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on allogeneic hematopoietic stem cell transplantation for multiple myeloma, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-23Clinical Trial Update: Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma [Phase 3]
Phase 3 trial comparing bortezomib-melphalan conditioning vs melphalan for frontline transplant-eligible multiple myeloma patients; study st…
-
CLINICAL_TRIALS trial_result · 2022-05-19Clinical Trial Update: Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating ixazomib citrate, pomalidomide, dexamethasone with stem cell transplant in relapsed or refractory multiple…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex [Phase 3]
Phase 3 trial in relapsed/refractory multiple myeloma comparing daratumumab/pomalidomide/dexamethasone versus pomalidomide/dexamethasone; re…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma [Phase 2]
Phase 2 trial investigating autologous stem cell transplant followed by maintenance therapy in elderly multiple myeloma patients; results po…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating panobinostat, carfilzomib, and dexamethasone in relapsed or refractory multiple myeloma; study terminated with post…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy [Phase 4]
Phase 4 trial update on ferric carboxymaltose for treating iron-deficiency anemia in cancer patients with multiple myeloma on chemotherapy; …
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance [Phase 2]
Phase 2 clinical trial evaluating lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Panobinostat Biological Correlates Study [Phase 2]
Phase 2 clinical trial evaluating panobinostat with biological correlates in various lymphoma conditions has completed.
-
CLINICAL_TRIALS withdrawal · 2022-05-03Clinical Trial Update: A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma [Phase 4]
Phase 4 multicenter trial investigating ixazomib with pomalidomide or with lenalidomide and dexamethasone in relapsed/refractory multiple my…
-
CLINICAL_TRIALS trial_result · 2022-05-03Clinical Trial Update: Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating selinexor with high-dose melphalan before autologous stem cell transplantation in multiple myeloma; study complet…
-
FDA approval · 2022-05-02FDA Approved: BORTEZOMIB — Original Application (Hospira, Inc.)
FDA approved bortezomib under an original application, establishing its use in the treatment of multiple myeloma.
-
FDA approval · 2022-05-02FDA Approved: BORTEZOMIB — Original Application (Apotex Corp)
FDA approves Apotex Corp's original application for a generic Bortezomib product under ANDA205533.
-
FDA approval · 2022-05-02FDA Approved: BORTEZOMIB — Original Application (Eugia US LLC)
The FDA approved the original application for a generic Bortezomib product from Eugia US LLC (ANDA212825).